2017 awards FINALISTS

DOWNLOAD THE PROSPECTUS
SECURE YOUR PLACE

2017 PARTICIPATING COMPANIES INCLUDE

2017 awards FINALISTS 

#BMGalaDinner

2017 AWARDS FINALISTS

Click the image to DOWNLOAD the 2017 Finalist roster ebook

In addition to the live voting taking place at the Awards Ceremony on the 14th September, there is also a weighted public / community vote that will accompany those votes cast on the night.

You can submit your own vote once through the below link. Make it count!

VOTE NOW ON THE FINALISTS 


 

uk life science SPIN-OUT OF THE YEAR (<1 year FROM SPIN-OUT)

Open to privately owned Life Science companies and their Tech Transfer Office

Hosted by:     JA Kemp.jpg

Achilles Therapeutics, UCL, CRT and the Francis Crick Institute
Apollo Therapeutics, Imperial Innovations, UCLB and Cambridge Enterprise
Cardian, Imperial Innovations
Circadian Therapeutics, Oxford University Innovation
GammaDelta Therapeutics, KCL / Francis Crick Institute and CRT
Keapstone Therapeutics, University of Sheffield
Microbiotica, Wellcome Trust Sanger Institute
SuperX

 

UK LIFE SCIENCE YOUNG COMPANY OF THE YEAR (1-3 YEARS OLD)

Open to privately owned Life Science companies that are between 1 and 3 years on from incorporation.

Hosted by:Clinigen-3.png

Autolus
Artios Pharma
Auspherix
Benevolent AI
Freeline Therapeutics
NightstaRx
Orchard Therapeutics
Tusk Therapeutics

 

UK PRIVATE LIFE SCIENCE GROWTH COMPANY OF THE YEAR (>3 YEARS OLD) 

Open to privately owned Life Science companies that are greater than 3 years on from incorporation.

Bicycle Therapeutics
Cell Medica
Crescendo Biologics
F-Star
Immunocore
Kymab
MISSION Therapeutics
PsiOxus Therapeutics

 ENQUIRE ABOUT HOSTING AN AWARD

Uk life science DEAL OF THE YEAR

Open to either private or public life science companies, their Pharma partners and their Advisors.

Abzena and undisclosed San Diego-based Biopharma - $300m licensing deal
Bicycle Therapeutics and AstraZeneca - $1bn peptide collaboration
Crescendo Biologics - Takeda $790m cancer collaboration
F-Star and Merck – €1bn immuno-oncology collaboration
GammaDelta Therapeutics and Takeda - $100m investment / acquisition option
PsiOxus Therapeutics and BMS - $936m deal
Summit Therapeutics and Sarepta - $584m+ DMD pipeline EU license pact
Vectura and Skyepharma merger

 ENQUIRE ABOUT HOSTING AN AWARD 

UK PRIVATE finance raise of THE YEAR (£25m)

Open to privately owned Life Science companies and their lead investors.

Artios Pharma - £25m, Series A, SVLS, Touchstone Innovations, Arix Bioscience, Merck Ventures, Abbvie, CRT Pioneer Fund
Achilles Therapeutics - £13.2m, Seed Financing, Syncona, CRT Pioneer Fund and the UCL Technology Fund
ApcinteX - £14m Series A, Medicxi, Touchstone Innovations
Congenica - £10m, Series B, CIC, Amadeus Capital Partners, Parkwalk Advisors
NeRRe Therapeutics - £23m, Series B - Advent Life Sciences, Fountain Healthcare Partners, Orbimed, Forbion
Oxular - £15.5m, Series A, V-Bio Ventures,Touchstone Innovations, Consort Medical, NeoMed and Hovione Scientia
Pulmocide - £24m, Series B, SR-One, SV Life Sciences, Touchstone Innovations, JJVC, F-Prime Capital

 ENQUIRE ABOUT HOSTING AN AWARD 

UK PRIVATE FINANCE RAISE OF THE YEAR (>£25M)

Open to privately owned Life Science companies and their lead investors.

Atlas Genetics - £28.3m, Series D, Novartis Venture Funds, Consort Medical plc, Johnson & Johnson Innovation - JJDC, Inc., LSP, BB Biotech Ventures, RMI Partners and Technology Venture Partners, YFM Equity Partners and Wondfo Biotech 
Bicycle Therapeutics - £40m, Series B, Vertex Ventures, Cambridge Innovation Capital, Longwood Fund. Novartis VG, SR-One, SVLS and Atlas Venture
Carrick Therapeutics - £74m, Series A, ARCH Venture Partners and Woodford Investment Management, Cambridge Enterprise, Evotec AG, Google Ventures, Lightstone Venture and Cambridge Innovation Capital
Cell Medica - £60m, Series C, Touchstone Innovations, Invesco Perpetual and Woodford Investment Management
F2G - £46.5m, Series E, Sectoral Asset Management, Novo A/S, Aisling Capital, Advent Life Sciences, Novartis VF, Sunstone, Merifin Capital
Kymab - £78m, Series C,ORI Healthcare Fund
Oxford Nanopore - £100m, Venture Financing, GT Healthcare Healthcare Partners, Woodford Investment Management and IP Group Plc.

 ENQUIRE ABOUT HOSTING AN AWARD

UK LIFE SCIENCE IPO OF THE YEAR 

Open to newly publicly listed Life Science companies and their Advisors.

ConvaTec - £1,465m raise, issue price £2.25p (CTEC:LSE)
CREO Medical - £21.5m raise, issue price £0.76p (CREO:LSE)
Medica Group - £15m raise, issue price £1.35p (MGP:LSE)
Oxford Biodynamics - £20m raise, issue price £1.58p (OBD:LSE)
SkinBio Therapeutics - £4.5m raise, issue price £0.09p (SBTX:LSE)
Verona Pharma - $78m raise, issue price $13.50 (VRNA:US NASDAQ)
Widecells - £2m raise, issue price £0.113p (WDC:LSE)

 ENQUIRE ABOUT HOSTING AN AWARD 

UK PUBLIC FINANCE RAISE OF THE YEAR 

Open to publicly listed Life Science companies and their Advisors. Raise must be non-IPO.

Abzena - £25m raised to expand further its service offering, capacity and capabilities
C4X Discovery - £7m raised to continue to build its existing pipeline of five preclinical assets
Genedrive - £6.5m raised to broaden the portfolio of its Genedrive tests, developed to fight infectious diseases
Midatech Pharma - £16m raised to expand and advance its oncology-focused development pipeline
Oxford BioMedica - £10m raised to fund progress on its discovery and pre-clinical projects
Scancell Holdings - £5m raised to fund clinical work on its pipeline of cancer immune-therapies
Verona Pharma - £44.7m raised to fund RPL554 through a phase 2b clinical trial in chronic obstructive pulmonary disease (COPD) patients and additional phase 2 studies in both COPD and cystic fibrosis

  ENQUIRE ABOUT HOSTING AN AWARD

UK PUBLIC LIFE SCIENCE COMPANY OF THE YEAR 

Open to pubicly owned Life Science companies only. 

Hosted by:      CMS Cameron Mckenna .png

Abzena
Adaptimmune
Astrazeneca
Clinigen
Horizon Discovery
Oxford BioMedica
Shield Therapeutics
Summit Therapeutics

ENQUIRE ABOUT HOSTING AN AWARD 

life science communication strategy of THE YEAR 

Open to private or public life science companies and their PR / IR and Strategic Communications Firm.

Astex Pharmaceuticals and Instinctif
Evgen Pharma and Buchanan
F2G and Hume Brophy
Heptares Therapeutics and Citigate Dewe Rogerson
Horizon Discovery and Consilium Strategic Communications
Optibiotix and Walbrook PR
Verona Pharma and FTI Consulting

 ENQUIRE ABOUT HOSTING AN AWARD 

uk PRIVATE AND PUBLIC life science ceo of THE YEAR 

Open to CEOs from both privately and publicly owned Life Science companies.

PRIVATE

David Chiswell, Kymab
John Beadle, PsiOxus Therapeutics
John Haurum, F-Star
Christian Itin, Autolus
Kevin Lee, Bicycle Therapeutics
Anker Lundemose, MISSION Therapeutics
Peter Pack, Crescendo Biologics
Gordon Sanghera, Oxford Nanopore

 ENQUIRE ABOUT HOSTING AN AWARD

PUBLIC

John Burt, Abzena
Shaun Chilton, Clinigen
John Dawson, Oxford BioMedica
Darrin Disley, Horizon Discovery
Clive Dix, C4X Discovery
Glyn Edwards, Summit Therapeutics
Dame Louise Makin, BTG
James Ward-Lilley, Vectura

ENQUIRE ABOUT HOSTING AN AWARD